{"id":"W2774483419","doi":"10.1158/2159-8290.cd-17-1119","title":"First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study","year":2017,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":418,"is_retracted":false,"has_abstract":true,"ca_institutions":"Phenomenome Discoveries (Canada)","funders":"","keywords":"Medicine; Adverse effect; Nausea; Neuroblastoma RAS viral oncogene homolog; Cohort; Response Evaluation Criteria in Solid Tumors; Tolerability; Internal medicine; Cancer; Pharmacokinetics; MEK inhibitor; Oncology; Gastroenterology; MAPK/ERK pathway; Pharmacology; Clinical trial; Phases of clinical research; Kinase; Colorectal cancer; KRAS","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001666246,0.0008991328,0.00112741,0.0002005308,0.0002682318,0.0006652549,0.0004721,0.0005014639,0.001310685],"category_scores_gemma":[0.0005273176,0.0002767356,0.001117932,0.0002656413,0.0004309842,0.0005333196,0.0002017389,0.002157013,0.0003887187],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008626361,"about_ca_system_score_gemma":0.0008658,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008230916,"about_ca_topic_score_gemma":0.001939519,"domain_scores_codex":[0.9996195,0.0001622948,0.00002541927,0.00005493962,0.00005588095,0.00008202516],"domain_scores_gemma":[0.9996344,0.00006049642,0.00007333923,0.00003800579,0.00003573638,0.0001580533],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2447366,0.08737255,0.03063749,0.00100469,0.002437976,0.0006830447,0.0008569576,0.008679187,0.2647606,0.0003688026,0.008877063,0.3495851],"study_design_scores_gemma":[0.2620578,0.5740362,0.1096443,0.00008631465,0.001564805,0.001756804,0.0001783741,0.006860142,0.035298,0.0003445342,0.008083727,0.0000890262],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9968455,0.001172417,0.0003510807,0.0002038695,0.00002609394,0.0003490873,0.0003694515,0.00005174294,0.0006305982],"genre_scores_gemma":[0.9961303,0.0007493975,0.0009458842,0.0002806802,0.00003747377,0.0001794007,0.001072057,0.00001941327,0.0005852729],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001666246,"threshold_uncertainty_score":0.00881207,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01034731323142016,"score_gpt":0.2735128579624377,"score_spread":0.2631655447310176,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}